Ed Tweddell (c. 1941 – 4 August 2005) was an Australian businessperson. He was best known for his role as CEO of Australia's largest indigenous pharmaceutical manufacturer F H Faulding[1] and as Chairman of Ansell.[2] He also served on the board of a number of significant private and public sector organisations including the National Australia Bank, Australia Post and the Commonwealth Scientific and Industrial Research Organisation (CSIRO).
Early life and career
Tweddell was born in Brisbane and graduated in science and medicine from the University of Queensland. Dr Tweddell started his career as a medical practitioner before obtaining a job with Pfizer Inc. in 1976. At Pfizer, Tweddell worked on drug development and medical relations. In 1986, Tweddell was appointed CEO and President of a Japanese healthcare company and stayed with that company for a couple of years.
F H Faulding
Tweddell returned to Australia in 1988 as Managing Director of F. H. Faulding & Co, a pharmaceutical company based in Adelaide. It was Australia's leading native pharmaceutical company. As CEO, Faulding entered into a joint venture with the CSIRO to develop new drugs. He also advocated Federal Government funding for pharmaceutical research given that the Pharmaceutical Benefits Scheme. Under the Keating Government, pharmaceutical companies were offered incentives under the Factor f scheme to develop Australia's pharmaceutical industry. Following a Productivity Commission inquiry, the Factor f scheme was replaced by the Pharmaceutical Industry Investment Program. In 1999, Tweddell signed an agreement with the Federal Government where Faulding would receive $40 million in funding over five years in return for industry development.
Under Dr Tweddell, Faulding established Faulding Pharmaceuticals based in the northern hemisphere. By 2000, the company was receiving more than half of its revenue from overseas. The continued growth of Faulding led to Mayne Nickless buying the company leading to Tweddell's resignation as CEO and from the board in 2001. At that point, it was one of the biggest companies in South Australia.
Board Positions
Dr Tweddell's success at Faulding led to offers to sign on the boards of other companies. In 2001, he became the chairman of Ansell, where he led the restructure of the former Pacific Dunlop company by keeping the Ansell business and divesting unprofitable businesses.
In 1998, Tweddell was appointed as a director of the National Australia Bank, where he sat on a committee assessing business risk. He resigned in 2004 after the foreign exchange scandal led to the bank losing hundreds of millions of dollars. He was also the chair of biotechnology company Peptech, but resigned after three months following an argument with its management.
Tweddell was on the board of Australia Post since 2001 and the CSIRO since 2002.[3] He was a dedicated supporter of the arts, serving as the Chairman of the Adelaide Festival of Arts. He founded the Nepenthe Group winery in 1994 and was a former President of the Adelaide Hills Wine Region.
Tweddell died on 4 August 2005. According to some sources he was believed to have killed himself following an illness.[4]
References
- ↑ "Australia Council mourns Ed Tweddell | Australia Council". www.australiacouncil.gov.au. Australia Council. Retrieved 21 September 2018.
- ↑ "Ansell's Tweddell dead at 64". The Sydney Morning Herald. 6 August 2005. Retrieved 21 September 2018.
- ↑ "Leading SA business figure dies". ABC News. 5 August 2005. Retrieved 21 September 2018.
- ↑ Mayne, Stephen (30 August 2005). "Coming clean over board and CEO health issues". Crikey. Retrieved 21 September 2018.
External links
- Crown Content Who's Who in Australia 2005 North Melbourne 2005 page 1881
- Tweddell's Nepenthe page
- Adelaide Advertiser news report on death
- Courier Mail news report on death
- ABC Report on Faulding's overseas success 13 November 2000
- ABC report on Tweddell's resignation from Faulding
- Pharmaceutical Industry Investment Program funding at the Wayback Machine (archived 17 July 2005)
- Productivity Commission report into the Pharmaceutical Industry